Plus therapeutics announces share repurchase program

Austin, texas, oct. 31, 2023 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that its board of directors has approved a share repurchase program, with authorization to repurchase up to $500,000 of the company's outstanding common stock. the company intends to fund any share repurchases with available cash.
pstv Ratings Summary
pstv Quant Ranking